SI1937673T1 - Imidazolovi derivati kot inhibitorji TAFIa - Google Patents

Imidazolovi derivati kot inhibitorji TAFIa

Info

Publication number
SI1937673T1
SI1937673T1 SI200632014T SI200632014T SI1937673T1 SI 1937673 T1 SI1937673 T1 SI 1937673T1 SI 200632014 T SI200632014 T SI 200632014T SI 200632014 T SI200632014 T SI 200632014T SI 1937673 T1 SI1937673 T1 SI 1937673T1
Authority
SI
Slovenia
Prior art keywords
tafia
inhibitors
imidazole derivatives
imidazole
derivatives
Prior art date
Application number
SI200632014T
Other languages
English (en)
Inventor
Christopher Kallus
Holger Heitsch
Volkmar Wehner
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of SI1937673T1 publication Critical patent/SI1937673T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SI200632014T 2005-10-15 2006-09-30 Imidazolovi derivati kot inhibitorji TAFIa SI1937673T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102005049385A DE102005049385A1 (de) 2005-10-15 2005-10-15 Imidazolderivate als Inhibitoren von TAFIa
EP06792327.6A EP1937673B1 (de) 2005-10-15 2006-09-30 Imidazolderivate als inhibitoren von tafi-a
PCT/EP2006/009500 WO2007045339A1 (de) 2005-10-15 2006-09-30 Imidazolderivate als inhibitoren von tafi-a

Publications (1)

Publication Number Publication Date
SI1937673T1 true SI1937673T1 (sl) 2016-02-29

Family

ID=37733974

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200632014T SI1937673T1 (sl) 2005-10-15 2006-09-30 Imidazolovi derivati kot inhibitorji TAFIa

Country Status (12)

Country Link
US (1) US8044208B2 (sl)
EP (1) EP1937673B1 (sl)
JP (1) JP5266053B2 (sl)
CY (1) CY1117379T1 (sl)
DE (1) DE102005049385A1 (sl)
DK (1) DK1937673T3 (sl)
ES (1) ES2558874T3 (sl)
HU (1) HUE026577T2 (sl)
PL (1) PL1937673T3 (sl)
PT (1) PT1937673E (sl)
SI (1) SI1937673T1 (sl)
WO (1) WO2007045339A1 (sl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009103432A2 (en) * 2008-02-21 2009-08-27 Sanofi-Aventis Covalently binding imaging probes
CA2741783A1 (en) 2008-10-29 2010-05-06 Taisho Pharmaceutical Co., Ltd. Compounds having tafia inhibitory activity
MX358628B (es) 2010-03-18 2018-08-28 Daiichi Sankyo Co Ltd Derivado de imidazol sustituido con cicloalquilo.
CN102884053B (zh) * 2010-03-18 2016-03-02 第一三共株式会社 环丙烷甲酸衍生物
KR101799429B1 (ko) 2010-05-03 2017-11-21 에스케이바이오팜 주식회사 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
WO2014198620A1 (en) 2013-06-10 2014-12-18 Sanofi Macrocyclic urea derivatives as inhibitors of tafia, their preparation and their use as pharmaceuticals
BR112022011917A2 (pt) 2019-12-20 2022-09-06 Tenaya Therapeutics Inc Fluoroalquil-oxadiazois e seus usos

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001276605A1 (en) * 2000-08-17 2002-02-25 Pfizer Inc. Substituted imidazoles as tafia inhibitors
WO2003013526A1 (en) * 2001-08-08 2003-02-20 Merck & Co. Inc. Anticoagulant compounds
BR0307033A (pt) * 2002-01-22 2004-12-07 Pfizer ácidos 3-(imidazolil)-2-aminopropanóicos para o uso como inibidores tafi-a para o tratamento de doenças trombóticas

Also Published As

Publication number Publication date
US20080262028A1 (en) 2008-10-23
DK1937673T3 (en) 2016-01-25
EP1937673B1 (de) 2015-10-21
DE102005049385A1 (de) 2007-04-19
CY1117379T1 (el) 2017-04-26
PL1937673T3 (pl) 2016-03-31
PT1937673E (pt) 2016-02-08
WO2007045339A1 (de) 2007-04-26
ES2558874T3 (es) 2016-02-09
JP5266053B2 (ja) 2013-08-21
US8044208B2 (en) 2011-10-25
HUE026577T2 (hu) 2016-06-28
EP1937673A1 (de) 2008-07-02
JP2009511516A (ja) 2009-03-19

Similar Documents

Publication Publication Date Title
IL194582A0 (en) Condensed imidazole derivatives as aromatase inhibitors
IL178672A0 (en) Imidazole derivatives used as tafia inhibitors
HK1133650A1 (en) Hydantoin derivatives used as mmp inhibitors
IL197955A0 (en) Imidazolone and imidazolidinone derivatives as 11b-hsd1 inhibitors for diabetes
IL198247A0 (en) Indazole derivatives useful as l-cpt1 inhibitors
HK1135391A1 (en) Triazole derivatives as kinase inhibitors
IL200047A0 (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
EP2192838A4 (en) HETEROCYCLIC NEKROPTOSIS HEMMER
IL196590A0 (en) Acrylamide derivatives as fab i inhibitors
IL193482A0 (en) Hydantoin based kinase inhibitors
EP2336123A4 (en) HETEROCYCLIC COMPOUND AS INHIBITOR OF PROTEIN KINASE
HK1151291A1 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
EP2300438A4 (en) IMIDAZOLE DERIVATIVES AS FAAH INHIBITORS
ZA200904175B (en) Imidazole derivatives as kinesin spindle protein inhibitors (EG-5)
HUE026577T2 (hu) Imidazol-származékok mint TAFI-a inhibitorok
ZA201007431B (en) Imidazolidinone derivatives as 11b-hsd1 inhibitors
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
HK1108435A1 (en) Hydantoin derivatives useful as metalloproteinase inhibitors
PL2104497T3 (pl) Pochodne sulfamidu jako inhibitory TAFIa
IL193981A0 (en) Novel heterocyclic nf-kb inhibitors
ZA200905235B (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
ZA200806993B (en) Hydantoin based kinase inhibitors